Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F. Kelley, Renu Singh, Maribel Acevedo-Quiñones et al.|New England Journal of Medicine|2024Cited by 260
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and SpainDeanna Kerrigan, Miranda Murray, Paige Hammond et al.|PLoS ONE|2018Cited by 179
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Jason Flamm, Peter Ruane et al.|The Lancet HIV|2021Cited by 91
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialOnyema Ogbuagu, Hui Wang, Nicolas Margot et al.|The Lancet HIV|2023Cited by 71
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trialsFrançois Raffi, Sharon Walmsley, Anita Rachlis et al.|AIDS|2014Cited by 57